AUSTIN, Texas, March 3, 2015 (GLOBE NEWSWIRE) — LDR Holding Corporation (Nasdaq:LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, announced today that it has entered into a worldwide distribution agreement with Sentio, LLC to distribute the SentioMMG ®nerve mapping system. SentioMMG smart-sensors employ accelerometer technology to sensitively measure when muscle contraction occurs, as a means to alert surgeons of motor nerve location.
Sentio offers a patented nerve location technology facilitating minimally invasive access to the spine. It is intended to locate and map motor nerve roots and their peripheral extensions originating from spinal levels C3-T1 and L2-S2.
“LDR’s Avenue ® L lateral lumbar cage with VerteBRIDGE ® plating technology is an innovative spinal construct featuring a lumbar cage optimized for placement via a lateral approach and integrated plate fixation that can be inserted without requiring additional exposure,” said Sean Parker, Vice President of Market Development for Sentio. “Adding SentioMMG to the LDR product portfolio completes the offering, makes the entire procedure highly efficient, and delivers full control to the operative surgeon.”
“Providing safe and efficient access is a key aspect to LDR’s success in the lateral lumbar market,” commented Joe Ross, LDR’s Executive Vice President of Global Marketing. “Our partnership with Sentio addresses that need and demonstrates our dedication to bringing innovative technologies to spine surgeons and their patients. We are very excited to offer SentioMMG through our LDR sales network.”
About Sentio, LLC
SentioMMG smart-sensors employ a proprietary technology, using non-invasive accelerometer-based sensors to measure MMG (mechanomyography) activity, or the mechanical “twitch” associated with muscle contraction. The result is an intuitive, surgeon-directed tool for establishing safe access in a variety of surgical applications.
Sentio is currently cleared for use in the United States by the FDA to assist in locating and mapping motor nerves through the use of mechanomyographic signals and electrical stimulus of nerves. SentioMMG has a CE mark for use in the European Union and other markets.
